Core Viewpoint - The legal opinion letter from Shanghai Chengming Zhenzheng Law Firm confirms that SF Holding Co., Ltd. has complied with necessary legal procedures for adjusting the exercise price of its stock options under the 2022 A-share stock option incentive plan, reducing the exercise price from RMB 40.199 per share to RMB 39.761 per share [1][10]. Summary by Sections Adjustment Details - The adjustment of the exercise price is based on the company's 2024 A-share dividend distribution plan, which involves a cash dividend of RMB 4.40 per 10 shares, resulting in a new exercise price calculation [4][5]. - The formula for adjusting the exercise price is P = P0 - V, where P0 is the original exercise price and V is the dividend per share [5]. Approval and Authorization - The company has obtained necessary approvals and authorizations for the adjustment, including independent opinions from independent directors and compliance with relevant laws and regulations [6][10]. - The adjustment process involved the avoidance of conflicts of interest by related directors during the voting process [6][10]. Legal Compliance - The law firm asserts that the adjustment complies with the Company Law, Securities Law, and relevant management regulations, ensuring that the interests of the company and its shareholders are not harmed [7][10]. - The legal opinion emphasizes that the company must fulfill its information disclosure obligations as per legal requirements following the adjustment [10].

Core Viewpoint - SF Holding Co., Ltd. has adjusted the exercise price of its 2022 A-share stock option incentive plan from RMB 40.199 per share to RMB 39.761 per share following the implementation of a cash dividend distribution [1][6]. Summary by Sections Approval Process and Disclosure - The adjustment of the exercise price was approved during the 23rd meeting of the sixth board of directors held on August 28, 2025, and was based on the authorization from the company's second extraordinary general meeting in 2022 [1]. - The independent directors provided independent opinions on the adjustment [1]. Monitoring and Verification - The fifth supervisory board meeting verified the list of incentive objects and approved relevant documents related to the incentive plan [2]. - Throughout the public notice period, no objections were raised regarding the proposed list of incentive objects [2]. Adjustment Reasons and Results - The adjustment was necessitated by the cash dividend distribution plan announced on July 9, 2025, which involved a cash dividend of RMB 4.4 per 10 shares [6]. - The adjusted exercise price was calculated using the formula P = P0 - V, resulting in a new exercise price of approximately RMB 39.761 per share after accounting for the cash dividend [6]. Impact on the Company - The adjustment of the exercise price is not expected to have a significant impact on the company's financial status or operational results, nor will it affect the stability of the management team or the implementation of the stock option incentive plan [6]. Supervisory Board Opinion - The supervisory board confirmed that the adjustment complies with relevant laws and regulations and does not harm shareholder interests [6][7]. Legal Opinion - The legal opinion from Shanghai Chengming Zezheng Law Firm confirmed that the necessary approvals and authorizations for the adjustment have been obtained, aligning with the relevant regulations [7].

| 深圳市他山企业管理咨询有限公司 | 独立财务顾问报告 | | | --- | --- | --- | | 深圳市他山企业管理咨询有限公司 | | | | 关于格力博（江苏）股份有限公司 | | | | 独立财务顾问报告 | | | | 二〇二五年八月 | | | | 深圳市他山企业管理咨询有限公司 | | 独立财务顾问报 | | 告 | | | | 目 录 | | | | 深圳市他山企业管理咨询有限公司 | 独立财务顾问报告 | | | 释 义 | | | | 除非上下文文意另有所指，下列词语具有如下含义： | | | | 格力博、公司 指 格力博（江苏）股份有限公司 | | | | 2024 格力博（江苏）股份有限公司 | 年股票期权激励计 | | | 本激励计划 指 | | | | 划 | | | | 2024 《格力博（江苏）股份有限公司 | 年股票期权激励 | | | 《股权激励计划（草案）》 指 | | | | 计划（草案）》 | | | | 《深圳市他山企业管理咨询有限公司关于格力博（江 | | | | 独立财务顾问报告、本报告 指 苏）股份有限公司 2024 | 年股票期权激励计划预留授予 ...

北京浩天（深圳）律师事务所 关于 广电计量检测集团股份有限公司 部分股票期权以及回购注销部分限制性股票事项的 法律意见书 二〇二五年八月 北京浩天（深圳）律师事务所 法律意见书 北京浩天（深圳）律师事务所 关于广电计量检测集团股份有限公司 及回购注销部分限制性股票事项的 法律意见书 致：广电计量检测集团股份有限公司 北京浩天（深圳）事务所（以下简称"本所"）接受广电计量检测集团股 份有限公司（以下简称"广电计量"或"公司"）的委托，作为公司实施2023 年股票期权与限制性股票激励计划（以下简称"本激励计划"）的专项法律顾 问。 四、本所仅就与公司本次注销和本次回购注销有关的法律问题发表意见， 而不对公司本次注销和本次回购注销所涉及的标的股票价值、考核标准等方面 的合理性以及会计、财务等非法律专业事项发表意见。在本法律意见书中对有 关财务数据或结论进行引述时，本所已履行了普通注意义务，但该等引述并不 视为本所对这些数据、结论的真实性和准确性作出任何明示或默示保证。 本所及经办律师根据《中华人民共和国公司法》（以下简称"《公司法》" ）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股 权激励管 ...

Group 1 - The company held its ninth supervisory board's fourth meeting on August 27, 2025, which complied with relevant laws and regulations [1][2] - The supervisory board approved adjustments to the 2024 employee stock ownership plan, changing the method of equity disposal in case of unmet performance targets [1][2] - The company will repurchase and cancel 1,737,250 shares that did not unlock due to unmet performance targets in the 2024 employee stock ownership plan [2][3] Group 2 - The supervisory board approved the adjustment of the exercise price for the 2024 stock option incentive plan from 11.41 yuan to 11.21 yuan per share [4][5] - The board confirmed that the adjustment of the exercise price complies with relevant regulations and does not harm the interests of the company and its shareholders [4][5] - The board also approved the cancellation of 938,750 stock options due to unmet performance targets and the departure of some incentive recipients [5][6] Group 3 - The company prepared its 2025 semi-annual report and summary, which accurately reflects its operational results and financial status for the first half of 2025 [6][7] - The supervisory board found that the report's preparation and review process complied with all relevant regulations and internal management systems [6][7] - The board approved a special report on the storage and actual use of raised funds for the first half of 2025, confirming compliance with regulations and no misuse of funds [8]

Financial Data and Key Metrics Changes - The meeting discussed the election of directors and the approval of an amendment to the stock option plan, which included an increase of 166,724 shares available for issuance [4][7] - The appointment of Witham Smith and Brown P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified [7][8] Business Line Data and Key Metrics Changes - No specific financial data or metrics related to individual business lines were provided during the meeting [10] Market Data and Key Metrics Changes - No specific market data or metrics were discussed in the meeting [10] Company Strategy and Development Direction - The company is focused on advancing its Phase I clinical trial, which includes a wide range of tumor types [10] - Future announcements regarding specific results from the clinical trial are expected in September [11] Management's Comments on Operating Environment and Future Outlook - Management indicated that the trial is an all-comers clinical trial, allowing participation from patients with various solid tumors [10] - There is an ongoing interest in the company's clinical studies, with a total of 16 patients treated in the Phase I trial [11] Other Important Information - The meeting concluded with the acknowledgment of shareholder interest and the adjournment of the Annual Meeting of Stockholders [12] Q&A Session Summary Question: How many patients are currently undergoing Transcode clinical studies? How many have dropped out and for what reasons? Are there patients with demonstrated tumor regressions so far? - The company reported that a total of 16 patients have been treated in the Phase I clinical trial, with more details expected to be announced in September [10][11]

Financial Data and Key Metrics Changes - The meeting reported the election of directors and the approval of an amendment to the stock option plan, indicating a stable governance structure and potential for future growth [7][8]. Business Line Data and Key Metrics Changes - No specific financial data or metrics related to individual business lines were provided during the meeting [9]. Market Data and Key Metrics Changes - The company is currently conducting a Phase I clinical trial with a total of 16 patients treated, indicating ongoing research and development efforts in the market [10][11]. Company Strategy and Development Direction - The company is focused on advancing its clinical trials and plans to announce specific results in September, reflecting a commitment to transparency and progress in its research initiatives [11]. Management Comments on Operating Environment and Future Outlook - Management acknowledged the diverse range of tumor types represented in the clinical trial, suggesting a broad market approach and adaptability to various patient needs [10]. Other Important Information - The meeting concluded with a commitment to provide further details on clinical trial results in the near future, highlighting the company's proactive communication strategy [11]. Q&A Session Summary Question: How many patients are currently undergoing Transcode clinical studies? - The company reported that 16 patients have been treated in the Phase I clinical trial, with more details expected to be announced in September [10][11].

Core Viewpoint - Shanghai Zhenhua Heavy Industries Group Co., Ltd. is implementing a stock option incentive plan for 2023, which includes adjustments to the exercise price and the cancellation of certain stock options [1][10]. Summary by Sections Legal Framework - The legal opinion is based on various laws and regulations, including the Company Law, Securities Law, and specific guidelines for stock option incentives [2][3]. Approval and Authorization - The company has completed necessary approvals and authorizations for the incentive plan, including resolutions from the board and supervisory committee [4][5][10]. Stock Option Details - The initial grant involves 75.23 million stock options to 345 incentive targets, with an exercise price set at 3.31 yuan per share, effective from June 17, 2024 [6][7][10]. Adjustments to Exercise Price - The exercise price for the stock options has been adjusted to 3.26 yuan per share due to a cash dividend distribution of 0.55 yuan per share [8][11][12]. Cancellation of Stock Options - A total of 850,000 stock options will be canceled due to three incentive targets no longer qualifying, reducing the number of initial grants to 73.98 million options [11][12]. Information Disclosure - The company is committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations throughout the incentive plan's implementation [12].

证券代码：600320 900947 证券简称：振华重工 振华 B 股 公告编号：临 2025-041 上海振华重工（集团）股份有限公司 关于注销公司 2023 年股票期权激励计划 部分股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海振华重工（集团）股份有限公司（以下简称公司或振华重工）2023 年年度股东大会授权，公司于 2025 年 8 月 29 日召开第九届董事会第十五次会议， 审议通过了《关于审议 <注销公司 ensp="ensp" 年股票期权激励计划部分股票期权="年股票期权激励计 划部分股票期权"> 的议 一、已履行的决策程序和信息披露情况 第十七次会议，审议通过了《关于审议 <振华重工长期股权激励计划 及="及" 草案="草案"> 其摘要>的议案》、《关于审议 <振华重工 ensp="ensp" 及="及" 年股票期权激励计划="年股票期权激励 计划" 草案="草案"> 其摘要>的议案》、《关于审议 <振华重工 ensp="ensp" 年股票期权激励计划实施考核管="年股票期权激 励计划实 ...

Core Viewpoint - The company has made significant strategic moves, including land acquisition in Mexico and the purchase of remaining equity in a subsidiary, which are expected to enhance its operational capabilities and market presence in North America [5][6]. Group 1: Company Overview - The company is engaged in precision manufacturing and has been actively expanding its production capabilities [7]. - The company has not changed its controlling shareholder or actual controller during the reporting period [4]. Group 2: Financial Highlights - The company reported a total asset impairment provision of 27.91 million yuan for the first half of 2025, which will reduce the net profit attributable to shareholders by 22.64 million yuan [16][41]. - The company has not distributed cash dividends or bonus shares during the reporting period [2]. Group 3: Strategic Developments - The company plans to purchase land in Mexico for $308.55 million, approximately 22.18 million yuan, to support its production operations in North America [5]. - The company signed an agreement to acquire an additional 49% stake in a subsidiary, which will make it a wholly-owned subsidiary [6]. Group 4: Board and Supervisory Committee Decisions - The board of directors approved the half-year report and the special report on the use of raised funds, confirming compliance with relevant regulations [10][12]. - The supervisory committee also reviewed and approved the half-year report, affirming its accuracy and completeness [22][24]. Group 5: Stock Option Plan - The company has decided to cancel 400,000 stock options from the 2024 stock option incentive plan due to the departure of seven incentive targets [14][56]. - The cancellation of stock options is not expected to impact the company's financial status or operational results significantly [56].